JP2012509264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509264A5 JP2012509264A5 JP2011536397A JP2011536397A JP2012509264A5 JP 2012509264 A5 JP2012509264 A5 JP 2012509264A5 JP 2011536397 A JP2011536397 A JP 2011536397A JP 2011536397 A JP2011536397 A JP 2011536397A JP 2012509264 A5 JP2012509264 A5 JP 2012509264A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- lactide
- weight
- ester
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 24
- 229920000642 polymer Polymers 0.000 claims 24
- 239000007943 implant Substances 0.000 claims 20
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical group C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 10
- 229960003679 brimonidine Drugs 0.000 claims 10
- 150000002148 esters Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229920002988 biodegradable polymer Polymers 0.000 claims 6
- 239000004621 biodegradable polymer Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920003178 (lactide-co-glycolide) polymer Polymers 0.000 claims 4
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 229960001724 brimonidine tartrate Drugs 0.000 claims 4
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/272,548 | 2008-11-17 | ||
| US12/272,548 US9095506B2 (en) | 2008-11-17 | 2008-11-17 | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| PCT/US2009/063490 WO2010056598A2 (en) | 2008-11-17 | 2009-11-06 | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143227A Division JP2014184348A (ja) | 2008-11-17 | 2014-07-11 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509264A JP2012509264A (ja) | 2012-04-19 |
| JP2012509264A5 true JP2012509264A5 (enExample) | 2012-12-20 |
| JP5580832B2 JP5580832B2 (ja) | 2014-08-27 |
Family
ID=41698087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536397A Expired - Fee Related JP5580832B2 (ja) | 2008-11-17 | 2009-11-06 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
| JP2014143227A Pending JP2014184348A (ja) | 2008-11-17 | 2014-07-11 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143227A Pending JP2014184348A (ja) | 2008-11-17 | 2014-07-11 | 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US9095506B2 (enExample) |
| EP (1) | EP2355795B1 (enExample) |
| JP (2) | JP5580832B2 (enExample) |
| AU (3) | AU2009314266A1 (enExample) |
| CA (1) | CA2743837C (enExample) |
| ES (1) | ES2624448T3 (enExample) |
| WO (1) | WO2010056598A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| JP5937004B2 (ja) | 2009-05-18 | 2016-06-22 | ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 薬剤溶出眼内インプラント |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| EP2437684B1 (en) | 2009-06-03 | 2022-06-15 | ForSight Vision5, Inc. | Anterior segment drug delivery |
| NZ716349A (en) | 2009-11-09 | 2017-07-28 | Allergan Inc | Compositions and methods for stimulating hair growth |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US20120213840A1 (en) * | 2011-02-18 | 2012-08-23 | Valeant International (Barbados) Srl | Ocular strips |
| EP3494959A3 (en) | 2011-04-29 | 2019-09-11 | Allergan, Inc. | Sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| CA2848397C (en) | 2011-09-14 | 2022-04-26 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
| US20180126033A9 (en) | 2012-03-14 | 2018-05-10 | MAM Holdings of West Florida, L.L.C. | Collagen compositions and uses for biomaterial implants |
| CA2867203C (en) * | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
| EP2956096A1 (en) * | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| AU2014250937A1 (en) | 2013-04-12 | 2015-10-22 | Allergan, Inc. | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
| EP4046628A1 (en) | 2013-10-31 | 2022-08-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| WO2015179527A1 (en) * | 2014-05-23 | 2015-11-26 | Ocular Technologies Sarl | Topical formulations and uses thereof |
| AU2015266850B2 (en) | 2014-05-29 | 2019-12-05 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| ES2951202T3 (es) | 2014-07-28 | 2023-10-19 | Sun Pharma Advanced Res Co Ltd | Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco |
| KR20170046146A (ko) | 2014-08-13 | 2017-04-28 | 더 존스 홉킨스 유니버시티 | 각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자 |
| MX2017007873A (es) | 2014-12-15 | 2017-11-06 | Univ Johns Hopkins | Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares. |
| CN107206099A (zh) | 2015-01-20 | 2017-09-26 | 约翰霍普金斯大学 | 用于持续释放抗青光眼剂以控制眼内压的组合物 |
| HK1249460A1 (zh) | 2015-03-06 | 2018-11-02 | Aerie Pharmaceuticals, Inc. | 植入物施用器和植入物的施用方法 |
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| CN115337254A (zh) * | 2015-07-23 | 2022-11-15 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| JP6856620B2 (ja) * | 2015-07-27 | 2021-04-07 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ | 薬剤搭載ナノ樹脂粒子 |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US10441548B2 (en) | 2015-11-12 | 2019-10-15 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
| US9579350B1 (en) | 2016-02-25 | 2017-02-28 | MAM Holdings of West Florida, L.L.C. | Human amniotic fluid preparation having long-term stability |
| US20190022016A1 (en) | 2016-03-02 | 2019-01-24 | The Johns Hopkins University | Compositions for sustained release of anti-glaucoma agents to control intraocular pressure |
| CA3022830A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| AU2017321980B2 (en) | 2016-09-02 | 2020-04-30 | Alcon Inc. | Implant applicators |
| MX2019011242A (es) | 2017-03-23 | 2020-01-21 | Graybug Vision Inc | Farmacos y composiciones para el tratamiento de trastornos oculares. |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| EP3691618A1 (en) | 2017-10-06 | 2020-08-12 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| CN116650732A (zh) | 2018-01-08 | 2023-08-29 | 铸造疗法股份有限公司 | 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法 |
| US12458589B2 (en) | 2018-05-12 | 2025-11-04 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled release of therapeutic agents |
| AU2019294615A1 (en) * | 2018-06-25 | 2021-02-11 | ReacX Pharmaceuticals, Inc. | Implants for release of lipophilic or amphiphilic pharmaceutical substances |
| EP3843710A1 (en) | 2018-08-28 | 2021-07-07 | Foundry Therapeutics, Inc. | Polymer implants |
| CA3132635A1 (en) * | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
| JP7879845B2 (ja) | 2020-07-21 | 2026-06-24 | アラーガン、インコーポレイテッド | プロスタミドが高充填された眼内インプラント |
| EP4598504A2 (en) | 2022-10-05 | 2025-08-13 | Mireca Medicines GmbH | Microparticle and implant formulations for cgmp analog therapy |
| WO2025179071A1 (en) * | 2024-02-20 | 2025-08-28 | Bausch + Lomb Ireland Limited | Sustained-release drug delivery compositions for treating ocular diseases |
| USD1137672S1 (en) | 2024-08-27 | 2026-07-28 | Glaukos Corporation | Drug eluting ocular implant |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2054102A (en) | 1936-09-15 | Voting machine | ||
| NL64744C (enExample) | 1940-03-09 | |||
| US2401708A (en) | 1943-01-19 | 1946-06-04 | Eastman Kodak Co | Range finder |
| US2401408A (en) | 1944-05-03 | 1946-06-04 | Harold S Bixby | Lock for fluorescent lamps |
| US2743837A (en) | 1953-06-01 | 1956-05-01 | Leon J Cook | Lead sleeve expanding device |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5264188A (en) | 1991-01-22 | 1993-11-23 | Phillips Petroleum Company | Multi-stage hydrotreating process and apparatus |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5856329A (en) | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| US6066675A (en) | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| EP0992244A4 (en) | 1997-07-02 | 2001-01-17 | Santen Pharmaceutical Co Ltd | SCLERAL PLUGS OF POLYLACTIC ACID |
| EP1003569B1 (en) | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
| AU775149B2 (en) | 1999-10-21 | 2004-07-22 | Alcon Inc. | Sub-tenon drug delivery |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US20010049369A1 (en) * | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| US6692759B1 (en) | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| WO2002058730A2 (en) | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| NZ533434A (en) | 2001-11-14 | 2006-11-30 | Alza Corp | Thixotropic gel composition for injectable deposition |
| EP1487498B1 (en) | 2002-03-18 | 2009-05-20 | Novartis AG | Topical composition comprising a cyclofructan, a carrier and a drug |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| MXPA05000632A (es) | 2002-07-15 | 2005-03-31 | Alcon Inc | Composiciones para implante farmaceuticas, lipofilas, no polimericas para uso intraocular. |
| US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| JP2006504741A (ja) * | 2002-10-08 | 2006-02-09 | アラーガン、インコーポレイテッド | 痴呆およびパーキンソン病の処置における（２−イミダゾリン−２−イルアミノ）キノキサリンの使用方法 |
| US7368126B2 (en) | 2002-11-06 | 2008-05-06 | Guohua Chen | Controlled release depot formulations |
| MXPA05007719A (es) | 2003-01-24 | 2005-09-30 | Control Delivery Sys Inc | Dispositivo de liberacion sostenida y metodo para la administracion ocular de agentes adrenergicos. |
| JP2005035235A (ja) * | 2003-07-18 | 2005-02-10 | Noritsu Koki Co Ltd | 画像露光装置 |
| US20050131372A1 (en) * | 2003-12-10 | 2005-06-16 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with removable protective wing portions |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20050244471A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US7135391B2 (en) * | 2004-05-21 | 2006-11-14 | International Business Machines Corporation | Polycrystalline SiGe junctions for advanced devices |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| WO2020217112A1 (en) | 2019-04-23 | 2020-10-29 | Raily S.R.L. | Modular railing suitable for variable installation slopes |
| US11902105B2 (en) | 2022-05-24 | 2024-02-13 | Red Hat, Inc. | Interactive graphical user interface for visualizing flow data in a programmable network switch |
-
2008
- 2008-11-17 US US12/272,548 patent/US9095506B2/en active Active
-
2009
- 2009-11-06 ES ES09799446.1T patent/ES2624448T3/es active Active
- 2009-11-06 CA CA2743837A patent/CA2743837C/en active Active
- 2009-11-06 AU AU2009314266A patent/AU2009314266A1/en not_active Abandoned
- 2009-11-06 JP JP2011536397A patent/JP5580832B2/ja not_active Expired - Fee Related
- 2009-11-06 EP EP09799446.1A patent/EP2355795B1/en not_active Not-in-force
- 2009-11-06 WO PCT/US2009/063490 patent/WO2010056598A2/en not_active Ceased
-
2014
- 2014-07-11 JP JP2014143227A patent/JP2014184348A/ja active Pending
-
2015
- 2015-08-03 US US14/816,401 patent/US9522113B2/en not_active Expired - Fee Related
-
2016
- 2016-07-01 AU AU2016204582A patent/AU2016204582A1/en not_active Abandoned
- 2016-12-19 US US15/383,079 patent/US9861576B2/en not_active Expired - Fee Related
-
2018
- 2018-01-08 US US15/864,990 patent/US10471004B2/en active Active
- 2018-04-12 AU AU2018202557A patent/AU2018202557B2/en not_active Ceased
-
2019
- 2019-11-11 US US16/679,737 patent/US10842739B2/en not_active Expired - Fee Related
-
2020
- 2020-11-06 US US17/091,434 patent/US20210161809A1/en not_active Abandoned
-
2022
- 2022-07-15 US US17/812,893 patent/US20230285279A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | High performance PVA/lignin nanocomposite films with excellent water vapor barrier and UV-shielding properties | |
| WO2011109384A3 (en) | Biodegradable polymers for lowering intraocular pressure | |
| JP2010507451A5 (enExample) | ||
| JP2009532087A5 (enExample) | ||
| EA201170039A1 (ru) | Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения | |
| JP2018500394A5 (enExample) | ||
| US20090209558A1 (en) | Polymer formulations for delivery of bioactive materials | |
| WO2012054923A3 (en) | Therapeutic nanoparticles with high molecular weight copolymers | |
| JP2011525514A5 (enExample) | ||
| JP2012524826A5 (enExample) | ||
| JP7500659B2 (ja) | 架橋粒子 | |
| WO2011151356A3 (en) | Methods for the preparation of injectable depot compositions | |
| WO2007038625A3 (en) | Biodegradable nanocomposites with enhanced mechanical properties for soft tissue engineering. | |
| JP2013534981A5 (enExample) | ||
| JP2010537989A5 (enExample) | ||
| JP2012528155A5 (enExample) | ||
| JP2015508118A5 (enExample) | ||
| WO2011091205A3 (en) | Intracameral sustained release therapeutic agent implants | |
| JP2010528136A5 (enExample) | ||
| JP2007297460A5 (enExample) | ||
| RU2016149734A (ru) | Направленно доставляемые терапевтические наночастицы и способы их получения и использования | |
| CN103055354B (zh) | 一种生物可降解的医用手术防粘连膜及其制备方法 | |
| CN1665889A (zh) | 具有经提高的耐水性的生物降解性组合物及其制作工艺 | |
| JP2012503691A5 (enExample) | ||
| CN104640904B (zh) | 生物分解性高分子化合物 |